These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 527353)

  • 1. A study of the effect of sulphinpyrazone ('Anturan') on blood viscosity.
    Johnston RV; Lowe GD; Drummond MM; Forbes CD; Prentice CR
    Curr Med Res Opin; 1979; 6(4):271-3. PubMed ID: 527353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers.
    Pfister B; Imhof P; Wirz H
    Eur J Clin Pharmacol; 1978 Jun; 13(4):263-5. PubMed ID: 668783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of anticoagulant response to warfarin by sulphinpyrazone: a double-blind study in patients with prosthetic heart valves.
    Girolami A; Fabris F; Casonato A; Randi ML
    Clin Lab Haematol; 1982; 4(1):23-6. PubMed ID: 7067372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemodynamic effects of sulphinpyrazone on exercise responses in normal subjects.
    Forfar JC; Russell DC; Oliver MF
    Lancet; 1980 Oct; 2(8197):718-20. PubMed ID: 6106828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulphinpyrazone in post-myocardial infarction. Report from the Anturan Reinfarction Italian Study.
    Lancet; 1982 Jan; 1(8266):237-42. PubMed ID: 6120272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination.
    Miners JO; Foenander T; Wanwimolruk S; Gallus AS; Birkett DJ
    Eur J Clin Pharmacol; 1982; 22(4):321-6. PubMed ID: 7106168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol.
    Ferrara LA; Mancini M; Marotta T; Pasanisi F; Fasano ML
    Eur J Clin Pharmacol; 1986; 29(6):717-9. PubMed ID: 3519237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood rheology changes during bezafibrate treatment.
    Caimi G; Francavilla G; Romano A; Catania A; Santonocito G; Sarno A
    Br J Clin Pract; 1988 Nov; 42(11):456-8. PubMed ID: 3076782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of orally administered sulphinpyrazone (Anturan) on platelet aggregation in vitro.
    Pfister B; Godbillon J; Colussi D; Imhof P
    Thromb Res; 1980 Apr 1-15; 18(1-2):89-99. PubMed ID: 7404507
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of sulphinpyranzone (Anturan) on thrombo-elastography.
    Leutenegger F; Michot F
    J Int Med Res; 1978; 6(2):133-5. PubMed ID: 631414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings: The effect of sulphinpyrazone (Anturan) on immunologically derived thrombocytopenia and on platelet survival.
    White AM; Butler KD
    Thromb Diath Haemorrh; 1975 Nov; 34(2):553-4. PubMed ID: 128152
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostaglandin-kallikrein-renin system during acute sulphinpyrazone administration in healthy volunteers.
    Verschueren LJ; Boelaert J; Daneels R; Schurgers M; Van Eeghem P; Lijnen P; Amery A
    Methods Find Exp Clin Pharmacol; 1982; 4(6):425-9. PubMed ID: 6755104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol.
    Staiger C; Schlicht F; Walter E; Gundert-Remy U; Hildebrandt R; de Vries J; Wang NS; Harenberg J; Weber E
    Eur J Clin Pharmacol; 1983; 25(6):797-801. PubMed ID: 6141054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of sulphinpyrazone on whole blood thromboxane and prostacyclin generation in man.
    Badenhorst PN; Deckmyn H; Vermylen J
    Thromb Res; 1982 Oct; 28(1):59-66. PubMed ID: 6818710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulphinpyrazone metabolism during long-term therapy.
    Pedersen AK; Jakobsen P
    Br J Clin Pharmacol; 1981 Jun; 11(6):597-603. PubMed ID: 7272176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.
    Schlicht F; Staiger C; de Vries J; Gundert-Remy U; Hildebrandt R; Harenberg J; Wang NS; Weber E
    Eur J Clin Pharmacol; 1985; 28(1):97-103. PubMed ID: 3987792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verapamil disposition--effects of sulphinpyrazone and cimetidine.
    Wing LM; Miners JO; Lillywhite KJ
    Br J Clin Pharmacol; 1985 Mar; 19(3):385-91. PubMed ID: 3986090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged inhibition of ex vivo sodium arachidonate-induced platelet aggregation and malondialdehyde (MDA) production by sulphinpyrazone (Anturan) in man.
    Maguire ED; Pay GF; Wallis RB; White AM
    Thromb Res; 1981 Feb; 21(3):321-7. PubMed ID: 7245142
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of chronic metoprolol and sulphinpyrazone on human lymphocyte beta-adrenoceptors.
    De Blasi A; Cortellaro M; Costantini C
    Br J Clin Pharmacol; 1984 Jul; 18(1):45-50. PubMed ID: 6331481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.
    Bradbrook ID; John VA; Morrison PJ; Rogers HJ; Spector RG
    Br J Clin Pharmacol; 1982 Feb; 13(2):177-85. PubMed ID: 7059415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.